Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure; Coronary artery disease
- Focus Pharmacokinetics
- Sponsors Bayer
- 30 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2017 Planned End Date changed from 10 Aug 2017 to 7 Sep 2017.
- 08 Jun 2017 Status changed from not yet recruiting to recruiting.